Lilly drug for Alzheimer’s approved by FDA

Left diagram – normal brain. Right diagram – brain of a person with Alzheimer’s disease. Courtesy of ADEAR: “Alzheimer’s Disease Education and Referral Center, a service of the National Institute on Aging.” Two images combined by Garrondo. Wikimedia. Public Domain. Article by Jonathan Gardner. BioPharma Dive – July 2, 2024.

The Food and Drug Administration on Tuesday approved a new Alzheimer’s disease drug from Eli Lilly, several weeks after a panel of independent experts unanimously recommended its clearance. The drug, which Lilly will sell as Kisunla, is designed to slow Alzheimer’s progression by clearing from the brain a toxic, sticky protein called amyloid that […]

Click here to view original web page at www.biopharmadive.com